A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 [...]
Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 [...]
Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 [...]
Sandrine Cochin, et al. CLARA, Forum de la recherche en [...]
Laetitia Fend, et al. AACR, American Association for cancer Research, [...]
Faleh Husseini, et al. Annals of Oncology, February 2017, DOI: [...]
Gilda G. Hillman, et al. Journal for ImmunoTherapy of Cancer, [...]
Roland Kratzer, et al. AASLD & Hepatology, October 2016 - [...]
Patricia Kleinpeter, et al. OncoImmunology, October 2016 – Download the [...]
Johann Foloppe, et al. 10th International Meeting on Replicating Oncolytic [...]
Anita Spindler, et al. XXI International Poxvirus, Asfavirus and Iridovirus [...]